Mesoblast Limited (NASDAQ:MESO) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of Mesoblast Limited (NASDAQ:MESO) by 65.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,245 shares of the company’s stock after purchasing an additional 7,220 shares during the quarter. Geode Capital Management LLC’s holdings in Mesoblast were worth $361,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of MESO. Jane Street Group LLC boosted its position in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after acquiring an additional 26,959 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after purchasing an additional 1,213 shares during the last quarter. Ballentine Partners LLC purchased a new position in shares of Mesoblast during the 4th quarter worth approximately $222,000. R Squared Ltd acquired a new position in Mesoblast during the 4th quarter worth about $30,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Mesoblast during the 4th quarter worth approximately $134,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Trading Up 0.9 %

NASDAQ MESO opened at $12.05 on Friday. The business’s 50-day moving average price is $12.44 and its 200 day moving average price is $13.66. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast Limited has a 52-week low of $5.78 and a 52-week high of $22.00.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Cantor Fitzgerald upgraded shares of Mesoblast to a “strong-buy” rating in a research note on Monday, March 31st. Piper Sandler restated an “overweight” rating and set a $24.00 target price (up from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.00.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.